You are here: Industry Insights > INO-4800

News List

Inovio reports positive data from Phase II Covid-19 DNA vaccine trial pharmaceutical-technology
May 12, 2021
The Inovio vaccine Phase II trial assessed the safety, tolerability and immunogenicity of two doses of INO-4800 to detect optimal dose(s) for age groups, namely 18 to 50 years and 51 years and above, for the Phase III efficacy analysis.
INOVIO’s DNA COVID Vax Achieves Positive Results contractpharma
May 11, 2021
Phase 2 clinical trial shows INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800 prnasia
April 25, 2021
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced that it is planning for a predominantly ex-U.S. Phase 3 ...
Inovio may move COVID-19 vaccine trial overseas after funding from US ends expresspharma
April 25, 2021
Inovio said, depending on the results of its mid-stage trial, it would run the late-stage study for its vaccine candidate, INO-4800, with partners such as China’s Advaccine and the International Vaccine Institute.
INO-4800 COVID-19 vaccine provides cross-reactive immune responses against variants europeanpharmaceuticalreview
April 20, 2021
Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
Inovio’s Covid-19 vaccine induces immune responses against variants pharmaceutical-technology
April 19, 2021
Inovio has reported that results from a study of its DNA Covid-19 vaccine candidate INO-4800 showed it induced a robust T cell response in humans against all spike protein variants of concern.
INOVIO, Advaccine Enter Exclusive COVID-19 DNA Vax Pact contractpharma
January 05, 2021
Partnership adds Asian manufacturing resource to INOVIO's global manufacturing consortium for INO-4800.
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine prnasia
December 25, 2020
INOVIO announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine, an open access clinical journal published by The Lancet.
INOVIO Doses First Subject in INO-4800 Trial to Prevent COVID-19 americanpharmaceuticalreview
December 24, 2020
INOVIO has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy).
Inovio initiates dosing in Phase II segment of Covid-19 therapy trial pharmaceutical-technology
December 09, 2020
Biotechnology firm Inovio has dosed the first participant in a Phase II segment of its Phase II / III INovio INO-4800 Vaccine Trial for Efficacy (INNOVATE) trial analysing its Covid-19 vaccine candidate, INO-4800.

Previous page 1 2 3 4 Next page